10-Q: PowerUp Acquisition Corp. Reports Second Quarter 2024 Results Amidst Merger Termination

Sentiment:

Quarterly Report


PowerUp Acquisition Corp. reported a net loss for the second quarter of 2024 and terminated its merger agreement with Visiox Pharmaceuticals.

Delay expectedThe company extended the deadline to complete a business combination to February 17, 2025.
Capital raiseThe company may need to raise additional capital through loans or additional investments from its New Sponsor, shareholders, officers, directors, or third parties.The company's officers, directors and New Sponsor may, but are not obligated to, loan the company funds to meet the company's working capital needs.
Worse than expectedThe company reported a net loss for the quarter, compared to a net income in the same period last year.The company terminated its merger agreement, which is a negative development.The company has a significant working capital deficit.

Summary

  • PowerUp Acquisition Corp. reported a net loss of $602,258 for the three months ended June 30, 2024, compared to a net income of $1,811,817 for the same period in 2023.
  • The company's operating expenses for the quarter were $501,012, with interest income from the trust account at $169,912.
  • For the six months ended June 30, 2024, the net loss was $3,069,359, compared to a net income of $4,684,250 for the same period in 2023.
  • The company's total assets were $6,867,584, with $6,524,611 held in a trust account.
  • The company terminated its merger agreement with Visiox Pharmaceuticals on July 19, 2024, due to unmet closing conditions.
  • The company has a working capital deficit of $5,897,306 as of June 30, 2024.
  • The company has until February 17, 2025, to complete a business combination.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the net loss, the termination of the merger agreement, the working capital deficit, and the going concern uncertainty. The company faces significant challenges in completing a business combination.

Positives

  • The company has $6,524,611 in its trust account, which can be used for a business combination.
  • The company has extended the deadline to complete a business combination to February 17, 2025.

Negatives

  • The company reported a net loss of $602,258 for the three months ended June 30, 2024.
  • The company has a working capital deficit of $5,897,306.
  • The merger agreement with Visiox Pharmaceuticals was terminated.
  • The company's operating expenses were $501,012 for the three months ended June 30, 2024.
  • The company's disclosure controls and procedures were deemed not effective.

Risks

  • The company may not be able to complete a business combination by February 17, 2025.
  • The company may need to raise additional capital to continue operations.
  • The company's ability to continue as a going concern is in doubt.
  • The company's disclosure controls and procedures were deemed not effective.
  • The company identified a material weakness in internal controls over financial reporting.

Future Outlook

The company intends to continue evaluating other possible business combination targets, though there can be no assurance these evaluations or efforts will result in a business combination transaction. The company has until February 17, 2025 to complete a business combination.

Management Comments

  • The company's management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Warrants.
  • The company's management believes the company is not exposed to significant risks on its cash accounts.
  • The company's management does not believe the adoption of ASU 2023-09 will have a material impact on its condensed consolidated financial statements and disclosures.

Industry Context

This is a typical report for a special purpose acquisition company (SPAC) that is seeking a business combination. The termination of the merger agreement is a significant event that will likely impact the company's future plans.

Comparison to Industry Standards

  • The financial results are typical for a SPAC in its pre-acquisition phase, with minimal operating revenue and reliance on interest income from the trust account.
  • The termination of the merger agreement is a setback, as many SPACs struggle to find suitable targets and complete acquisitions.
  • The working capital deficit and the need for additional financing are common challenges for SPACs approaching their deadline for completing a business combination.
  • The company's disclosure controls and procedures were deemed not effective, which is a concern and needs to be addressed.
  • The material weakness in internal controls over financial reporting is a significant issue that needs to be resolved.

Related Party Transactions

  • The company has related party loans with the New Sponsor and its affiliates.
  • The company pays an administrative services fee to an affiliate of the Original Sponsor.
  • The New Sponsor purchased shares and warrants from the Original Sponsor.

Stakeholder Impact

  • Shareholders are negatively impacted by the net loss and the termination of the merger agreement.
  • Shareholders face uncertainty regarding the company's ability to complete a business combination.
  • The company's employees may be impacted by the uncertainty surrounding the company's future.
  • Creditors may be concerned about the company's working capital deficit and ability to repay debts.

Next Steps

  • The company intends to continue evaluating other possible business combination targets.
  • The company may need to raise additional capital.
  • The company needs to address the material weakness in internal controls over financial reporting.

Key Dates

DateDescription
2021-02-09PowerUp Acquisition Corp. was incorporated.
2021-02-16Original Sponsor purchased Class B ordinary shares.
2022-02-11Company effected a share dividend of Class B ordinary shares.
2022-02-17Registration statement for the company's IPO was declared effective.
2022-02-23Company consummated its IPO and private placement of warrants.
2023-05-18Company held an extraordinary general meeting and extended the business combination deadline to May 23, 2024.
2023-06-28Underwriters agreed to waive their entitlement to deferred underwriting commissions.
2023-07-14Company entered into a purchase agreement with the New Sponsor and Original Sponsor.
2023-08-18New Sponsor purchased shares and warrants from the Original Sponsor.
2023-12-21Company entered into a Loan and Transfer Agreement with the New Sponsor and SSVK.
2023-12-26Company entered into a Merger Agreement with Visiox Pharmaceuticals.
2024-01-09Company entered into a Loan and Transfer Agreement with the New Sponsor and Apogee.
2024-01-10Company entered into a Loan and Transfer Agreement with the New Sponsor and Sheth.
2024-03-05Company entered into First Subscription Agreements.
2024-05-09Company entered into Second Subscription Agreements.
2024-05-22Company held an extraordinary general meeting and extended the business combination deadline to February 17, 2025.
2024-06-06Parties to the Merger Agreement entered into an Amendment Agreement.
2024-06-30End of the quarterly period.
2024-07-19Company terminated the Merger Agreement with Visiox Pharmaceuticals.
2024-08-16Date of the report.

Keywords

SPAC, Merger, Acquisition, Business Combination, Trust Account, Financial Results, Net Loss, Working Capital, Redemption, Warrants

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.